Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors
about
Research Progress on the Role of ABC Transporters in the Drug Resistance Mechanism of Intractable EpilepsyDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryDrug-Drug Interactions with the NS3/4A Protease Inhibitor SimeprevirExpression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral DrugsDrug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Transport in technicolor: mapping ATP-binding cassette transporters in sea urchin embryos.Protection against oxidative stress in beta thalassemia/hemoglobin E erythrocytes by inhibitors of glutathione efflux transporters.Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.Plasma Micronutrient Concentrations Are Altered by Antiretroviral Therapy and Lipid-Based Nutrient Supplements in Lactating HIV-Infected Malawian Women.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamicsAssociation of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDSImpact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance.Pharmacogenetics of tenofovir treatment.ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies.Renal toxicity associated with tenofovir use.Drug transporter pharmacogenetics in nucleoside-based therapies.Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies.How much do antiretroviral drugs penetrate into the central nervous system?Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.Modulators of the human ABCC2: hope from natural sources?Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.Drug transporter gene expression in human colorectal tissue and cell lines: modulation with antiretrovirals for microbicide optimization.Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease.Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactionsCombination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.Expression of membrane drug efflux transporters in the sigmoid colon of HIV-infected and uninfected men.Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters.Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.
P2860
Q26780520-4B9C2593-D7AB-4856-B2C1-6CF7B75EA1ADQ28081272-2C4FB4F2-7431-4B87-B66E-69BBB2926EEEQ28084266-280A95CA-110C-4C01-8559-CC77CDAA01CEQ28548592-66AA0877-6CE4-4D9E-B2B7-C08BDBA003AAQ30249113-0AAB8C26-DDEF-4736-B25D-C619B9C2FAF6Q34173709-FAF68AE0-34BD-45CC-A543-D4C9302940BCQ34576893-5B81B751-0572-43FD-A75D-D726B2DF04A6Q35000765-5969E371-5C26-440F-B031-5D72437F6AF3Q35091774-6A33374B-08C3-4ACD-936C-71871CD9FC83Q35894292-37628595-CD97-4FFC-9468-F7E55C2DE40DQ36342657-2F92F3FB-2C31-4E29-8D4A-14EF49D459F0Q36362462-C00FFD0A-7521-49FC-8DFF-976CAF75B6F3Q36693543-4AF891F2-ADDD-4880-AF7F-E69A064A7664Q36708715-223E7E4E-9C89-4C08-ACA3-005B992D609BQ36887174-EC1B8D18-2E23-46F7-B7B9-30BDD3C3A354Q37076348-15EF54AC-3BB9-499C-8B78-7C0CE30723C5Q37204271-22263771-7233-4F76-911D-19874D31464DQ37232200-7255030A-0904-4A2C-B161-AC80101EB622Q37379470-18FEC4A3-9404-4EE3-A36E-F1BD6D4CFDF0Q37481442-DD01B492-DD38-4837-9148-4381D5E60AE4Q37618231-1C8F1D10-D914-4EC9-B02C-41A03FD89BE6Q37724178-BFC54469-37E6-4B5D-BFA5-B17A42574416Q37729160-AEF533E7-9AE8-488B-B800-617089284E33Q37760954-80A121D9-6D9D-449F-A6B1-891EB6E2FE03Q37963498-88FD8EAF-4213-4A75-9C2E-74F57A4C7098Q38003612-C9801B94-30B6-47B5-A664-D9592FE54A8EQ38207943-90A03981-10E2-454E-8E01-ECC9D03D969AQ38261574-DF0CC824-3841-4F28-B3FC-42023E0698CEQ38478413-BB069F80-427A-4B99-91D9-866D7EABDFCEQ38614964-E8D814EC-E087-4EE5-8DAF-7239755C2D0AQ38811832-8B94EA74-2DF9-44D4-AB17-8124AF2358E4Q38823939-57D4E521-B8AF-4EB6-96F1-F644DFC0AEB3Q38973971-7B43550A-AC0B-453F-9466-E632D7A21070Q39229674-D38905F6-EAF7-4869-A9AB-A0260871192BQ39434360-8716BD97-1A8E-446E-950A-055003D703FCQ41172510-91FA4479-D73E-4511-9A09-22903F668944Q41791556-532A7D6C-7FA4-4B63-AC97-B9E2F8E2A068Q42283655-BBD9D0A7-D7FD-4941-8181-85F7F255C929Q42491474-62BCF874-E828-4372-A17C-1746DE1B64ABQ43475720-2AA94BA4-49CA-40FE-B971-5A84CE4C4C3A
P2860
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Inhibition of MRP1/ABCC1, MRP2 ...... verse transcriptase inhibitors
@ast
Inhibition of MRP1/ABCC1, MRP2 ...... verse transcriptase inhibitors
@en
Inhibition of MRP1/ABCC1, MRP2 ...... verse transcriptase inhibitors
@nl
type
label
Inhibition of MRP1/ABCC1, MRP2 ...... verse transcriptase inhibitors
@ast
Inhibition of MRP1/ABCC1, MRP2 ...... verse transcriptase inhibitors
@en
Inhibition of MRP1/ABCC1, MRP2 ...... verse transcriptase inhibitors
@nl
prefLabel
Inhibition of MRP1/ABCC1, MRP2 ...... verse transcriptase inhibitors
@ast
Inhibition of MRP1/ABCC1, MRP2 ...... verse transcriptase inhibitors
@en
Inhibition of MRP1/ABCC1, MRP2 ...... verse transcriptase inhibitors
@nl
P2093
P356
P1476
Inhibition of MRP1/ABCC1, MRP2 ...... verse transcriptase inhibitors
@en
P2093
Dirk Theile
Heike Lindenmaier
Johanna Weiss
P356
10.1124/DMD.106.012765
P407
P577
2007-03-01T00:00:00Z